Clinical Trial to Evaluate Efficacy and Safety of Dupilumab in Localized Scleroderma

Inclusion Criteria: * Subject is a male or female ≥18 years of age on the day the study informed consent is signed * Out-patient status * Caucasian * Morphea (plaque type) or Generalized localized scleroderma (affecting at least three anatomic sites) * At least one lesions with lilac ring (active phase of the disease); * Activity of LS within the last 12 month (as defined by progression of size or new developing plaque) * For women of childbearing potential: negative pregnancy test at Visit 1 * For women of childbearing potential: Use of effective method of contraception from 4 weeks prior to enrolment, throughout study treatment until 12 weeks after the last IMP dose. * Written informed consent signed Exclusion Criteria: * Systemic immunosuppressive therapy or UV therapy less than 3 months before enrollment. * Participation in another trial of IMPs or devices parallel to, or less than 6 months before or previous participation in this trial * Pregnancy or breastfeeding mother * Diagnosis of other significant chronic inflammatory or autoimmune disorders. Patients with the following autoimmune disorders are excluded from the study: Multiple sclerosis, primary biliary cirrhosis, type I diabetes mellitus. Patients with the following autoimmune disorders are regarded as eligible: Lichen sclerosus, vitiligo, alopecia arthritis, thyroid diseases (e.g. Hashimoto disease). Patients with any autoimmune disorder not listed above should only be included after consultation with the pri…